Trends in Atrial Fibrillation and Prescription of Oral Anticoagulants and Embolic Strokes in Germany

被引:6
|
作者
Guelker, Jan-Erik [1 ,2 ]
Bufe, Alexander [1 ,2 ,4 ]
Klues, Heinrich [1 ,2 ]
Shin, Dong-In [1 ,2 ]
Blockhaus, Christian [1 ,2 ]
Gabriel, Nils-Holger [3 ]
Haverkamp, Wilhelm [5 ]
Kroeger, Knut [3 ]
机构
[1] Helios Clin Krefeld, Dept Cardiol, Heartctr Niederrhein, Lutherpl 40, D-47805 Krefeld, Germany
[2] Univ Cologne, Inst Heart & Circulat Res, Cologne, Germany
[3] Helios Clin Krefeld, Dept Vasc Med, Krefeld, Germany
[4] Univ Witten Herdecke, Witten, Germany
[5] Charite, Dept Internal Med & Cardiol, Berlin, Germany
关键词
Stroke; Embolic stroke; Vitamin K antagonists; Direct oral anticoagulants; Atrial fibrillation; RISK STRATIFICATION; PREVALENCE; WARFARIN;
D O I
10.1016/j.carrev.2018.07.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of the study was to compare trends in frequency of atrial fibrillation (AF) with the prescription rates of oral anticoagulants (OAC) and the incidence of embolic stroke (ES) from 2005 through 2014. Methods: Annual numbers of hospitalized patients with AF and ES were extracted from the Federal Bureau of Statistics. Defined daily doses (DDD) of prescribed OAC among outpatients were extracted from the insurance drug information system. Results: The number of cases hospitalized with the diagnosis AF increased continuously by 78.3% (1.25 Million in 2005 to 2.19 Million in 2014, p < 0.001), likewise frequency of ES increased by 89.0% (from 46,068 to 87,050, p < 0.001) and the number of prescribed DDD of OAC almost doubled by 105.4% (from 271,328 to 557,281, p < 0.001). There is an almost linear correlation between occurrence of AF and ES (R-2 = 0.9683). In contrast association between prescription rate of OAC and incidence of ES is not linear as there was a disproportional increase in OAC prescriptions beginning in the year 2010 that is not accompanied by a reduction of cases hospitalized with ES. Conclusions: Our analysis of drug treatment rates for OAC in outpatients and hospitalization rates for ES revealed a disproportional increase in prescription of OAC beginning in the year 2010 that does not affect the number of cases hospitalized with ES. (c) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:399 / 402
页数:4
相关论文
共 50 条
  • [1] Prescription Trends of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
    Loo, Simone Y.
    Dell'Aniello, Sophie
    Huiart, Laetitia
    Renoux, Christel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 569 - 569
  • [2] Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
    Pritchett, Ruth V.
    Bem, Danai
    Turner, Grace M.
    Thomas, G. Neil
    Clarke, Joanne L.
    Fellows, Rebecca
    Lane, Deirdre A.
    Jolly, Kate
    [J]. THROMBOSIS AND HAEMOSTASIS, 2019, 119 (02) : 294 - 307
  • [3] Atrial Fibrillation: How effective and safe are the direct oral Anticoagulants for Prevention of Strokes?
    Hohnloser, Stefan H.
    Vamos, Mate
    Diener, Hans-Christoph
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (10) : 750 - U60
  • [4] Socioeconomic Inequalities in the Prescription of Oral Anticoagulants in Stroke Patients With Atrial Fibrillation
    Sjolander, Maria
    Eriksson, Marie
    Asplund, Kjell
    Norrving, Bo
    Glader, Eva-Lotta
    [J]. STROKE, 2015, 46 (08) : 2220 - 2225
  • [5] PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study)
    Basaran, Ozcan
    Basaran, Nesrin Filiz
    Cekic, Edip Guvenc
    Altun, Ibrahim
    Dogan, Volkan
    Mert, Gurbet Ozge
    Mert, Kadir Ugur
    Akin, Fatih
    Soylu, Mustafa Ozcan
    Sancar, Kadriye Memic
    Biteker, Murat
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (04) : 384 - 391
  • [6] Prescription and switching patterns of direct oral anticoagulants in patients with atrial fibrillation
    de Vries, Tim A. C.
    Bavalia, Roisin
    Chu, Gordon
    Xiong, Helen
    van de Wiel, Kayleigh M.
    van Ballegooijen, Hanne
    Huisman, Menno V.
    Hemels, Martin E. W.
    Middeldorp, Saskia
    de Groot, Joris R.
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (06)
  • [7] Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
    Gorczyca, Iwona
    Jelonek, Olga
    Uzieblo-Zyczkowska, Beata
    Chrapek, Magdalena
    Maciorowska, Malgorzata
    Wojcik, Maciej
    Blaszczyk, Robert
    Kaplon-Cieslicka, Agnieszka
    Gawalko, Monika
    Budnik, Monika
    Tokarek, Tomasz
    Rajtar-Salwa, Renata
    Bil, Jacek
    Wojewodzki, Michal
    Szpotowicz, Anna
    Bednarski, Janusz
    Bakula-Ostalska, Elwira
    Tomaszuk-Kazberuk, Anna
    Szyszkowska, Anna
    Welnicki, Marcin
    Mamcarz, Artur
    Wozakowska-Kaplon, Beata
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 14
  • [8] Restraints to Anticoagulation Prescription in Atrial Fibrillation and Attitude Towards the New Oral Anticoagulants
    Pereira-Da-Silva, Tiago
    Souto Moura, Teresa
    Azevedo, Luisa
    Sa Pereira, Margarida
    Virella, Daniel
    Alves, Marta
    Borges, Luis
    [J]. ACTA MEDICA PORTUGUESA, 2013, 26 (02): : 127 - 132
  • [9] Trends in the utilization of warfarin and the new oral anticoagulants in atrial fibrillation patients
    Alalwan, Abdullah Abdulaziz
    Voils, Stacy A.
    Hartzema, Abraham
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 133 - 134
  • [10] Novel Oral Anticoagulants for Atrial Fibrillation
    Hankey, Graeme J.
    Eikelboom, John W.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (08)